Creative Touch Permanent Makeup and Aesthetics

β-Glucocerebrosidase (GCase, encoded by GBA) is a lysosomal hydrolase that cleaves the glucose moiety from glucosylceramide to produce free ceramide. In skin, it functions in the extracellular space of the lower stratum corneum, where it processes the glucosylceramide precursors secreted from lamellar bodies at the stratum granulosum–stratum corneum junction. Alongside acid sphingomyelinase – which processes the sphingomyelin-to-ceramide route in parallel – GCase completes the extracellular ceramide generation step that converts packaged precursors into the free ceramides the lamellar matrix integrates. ^[3]

pH Dependency

GCase has a pH optimum of approximately 5.2 and is localised precisely where acid mantle pH supports peak activity – the lower to middle stratum corneum. At neutral pH (7.4), its activity is essentially absent. This makes GCase a reliable functional indicator of acid mantle status: when surface pH measurements show alkaline shift, GCase activity can be assumed to be impaired, and the glucosylceramide-to-ceramide conversion step is incomplete regardless of how much ceramide synthesis occurred upstream. Topical pH-lowering interventions – including appropriately formulated leave-on acidic products – restore GCase activity within hours, which is the mechanism by which pH correction produces measurable improvements in lamellar lipid organisation without any ceramide supplementation. ^[1]

Gaucher Disease and the Ceramide Depletion Model

Gaucher disease – caused by homozygous loss-of-function GBA mutations – produces systemic glucosylceramide accumulation and serves as the clearest genetic proof of GCase’s ceramide conversion role. Skin findings in Gaucher disease include ichthyosis-like barrier disruption, directly reflecting the ceramide deficit from GCase absence. In atopic dermatitis, GCase activity has been found increased in affected children relative to healthy controls, likely representing a compensatory upregulation attempting to maximise ceramide production from available glucosylceramide substrate in the context of ceramide depletion from other routes. The compensation is insufficient to restore ceramide levels – which reflects both the upstream SPT suppression and aSMase impairment occurring simultaneously. ^[2]

For clinical context on the pH-dependent ceramide processing step as a whole, see the Acid Mantle entity. For ceramide subtype relevance, see Ceramides.